Advertisement
Organisation › Details
Centogene (Group)
CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization. Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our CENTOGENE Biodatabank, with over 800,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 285 peer-reviewed publications. By translating our data and expertise into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target and drug screening, clinical development, market access and expansion, as well as offering CENTOGENE Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases. To discover more about our products, pipeline, and patient-driven purpose, visit www.centogene.com and follow us on LinkedIn. *
Start | 2006-01-01 established | |
Industry | molecular diagnostics | |
Industry 2 | diagnostic services | |
Person | Stratton, Kim (Centogene 202202– CEO before Orphazyme + Shire Pharmaceuticals + Novartis) | |
Person 2 | Coego Rios, Miguel (Centogene 202206– CFO joined as EVP Finance + Legal in 2/22 before Orphazyme + Mundipharma + Shire) | |
Region | Rostock | |
Country | Germany | |
Street | 7 Am Strande | |
City | 18055 Rostock | |
Tel | +49-381-80113-400 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | E: 501 to 1,000 (2021-12-31) |
Currency | EUR | |
Annual sales | 189,923,000 (revenue (2021) 2021-12-31) | |
Profit | -46,852,000 (2021-12-31) | |
Cash | 17,818,000 (2021-12-31) | |
* Document for »About Section«: Centogene N.V.. (2/28/24). "Press Release: Centogene Explores Strategic Alternatives". Cambridge, MA, Rostock & Berlin. | ||
Record changed: 2024-03-13 |
Advertisement
More documents for Centogene (Group)
- [1] Centogene N.V.. (2/28/24). "Press Release: Centogene Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing". Cambridge, MA, Rostock & Berlin....
- [2] Centogene N.V.. (2/28/24). "Press Release: Centogene Explores Strategic Alternatives". Cambridge, MA, Rostock & Berlin....
- [3] Centogene N.V.. (6/27/23). "Press Release: Centogene and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE...
- [4] Centogene N.V.. (6/14/23). "Press Release: Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency". Cambirdge, MA, Rostock & Berlin....
- [5] Centogene N.V.. (11/3/22). "Press Release: Centogene Launches Rare and Neurodegenerative Disease Biodata Network". Cambridge, MA, Rostock & Berlin....
- [6] Centogene N.V.. (9/1/22). "Press Release: Centogene to Present at Upcoming Investor & Partnering Conferences in September". Cambridge, MA, Rostock & Berlin....
- [7] Centogene N.V.. (6/27/22). "Press Release: Centogene Announces Appointment of Miguel Coego Rios as Chief Financial Officer". Cambridge, MA, Rostock & Berlin....
- [8] Centogene N.V.. (2/1/22). "Press Release: Centogene Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan". Cambridge, MA, Rostock & Berlin....
- [9] Centogene N.V.. (2/1/22). "Press Release: Centogene Announces Nomination of Kim Stratton as Chief Executive Officer". Cambridge, MA, Rostock & Berlin....
- [10] Centogene N.V.. (1/20/22). "Press Release: Centogene Joins Forces with Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development". Cambridge, MA, Rostock & Berlin...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top